Sun Pharma Gets Brazil Approval for Semaglutide Injection

MT Newswires Live

Jul 30

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has received approval from Brazil's health regulator, ANVISA, to manufacture and market semaglutide injection for adults with inadequately controlled type 2 diabetes, according to a Wednesday filing on Indian bourses.

The company plans to launch the product in Brazil in the coming days through a partnership with Hypera Pharma. The treatment will be available as a pre-filled, multi-dose injectable pen in two strengths with once-weekly dosing.

Shares of the pharmaceutical company rose nearly 1% in morning trade on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2655428208"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2655428208\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2655428208?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 12:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655428208","market":"hk","top_or_hot":-1,"title":"Sun Pharma Gets Brazil Approval for Semaglutide Injection","media":"MT Newswires Live","content":"<html><body><p> Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has received approval from Brazil's health regulator, ANVISA, to manufacture and market semaglutide injection for adults with inadequately controlled type 2 diabetes, according to a Wednesday filing on Indian bourses.</p><p>The company plans to launch the product in Brazil in the coming days through a partnership with Hypera Pharma. The treatment will be available as a pre-filled, multi-dose injectable pen in two strengths with once-weekly dosing.</p><p>Shares of the pharmaceutical company rose nearly 1% in morning trade on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sun Pharma Gets Brazil Approval for Semaglutide Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSun Pharma Gets Brazil Approval for Semaglutide Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-30 12:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has received approval from Brazil's health regulator, ANVISA, to manufacture and market semaglutide injection for adults with inadequately controlled type 2 diabetes, according to a Wednesday filing on Indian bourses.</p><p>The company plans to launch the product in Brazil in the coming days through a partnership with Hypera Pharma. The treatment will be available as a pre-filled, multi-dose injectable pen in two strengths with once-weekly dosing.</p><p>Shares of the pharmaceutical company rose nearly 1% in morning trade on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWZS","symbol_name":"MSCI巴西小盘股ETF-iShares","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655428208","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655428208","pubTimestamp":1785386038,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sun Pharmaceutical Industries  has received approval from Brazil's health regulator, ANVISA, to manufacture and market semaglutide injection for adults with inadequately controlled type 2 diabetes, according to a Wednesday filing on Indian bourses.The company plans to launch the product in Brazil in the coming days through a partnership with Hypera Pharma. The treatment will be available as a pre-filled, multi-dose injectable pen in two strengths with once-weekly dosing.Shares of the pharmaceutical company rose nearly 1% in morning trade on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EWZS":"MSCI巴西小盘股ETF-iShares"},"translate_title":"Sun Pharma 索马鲁肽注射液获得巴西批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWZS":1.5},"content_text":"Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has received approval from Brazil's health regulator, ANVISA, to manufacture and market semaglutide injection for adults with inadequately controlled type 2 diabetes, according to a Wednesday filing on Indian bourses.The company plans to launch the product in Brazil in the coming days through a partnership with Hypera Pharma. The treatment will be available as a pre-filled, multi-dose injectable pen in two strengths with once-weekly dosing.Shares of the pharmaceutical company rose nearly 1% in morning trade on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}